Hydroxyurea and Pain History in Relation to Patient-Reported Outcomes Using PROMIS Measures and the Frequency of Assessments in Sickle Cell Disease Patients

Pediatr Blood Cancer. 2017 Jan;64(1):203. doi: 10.1002/pbc.26059. Epub 2016 May 17.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anemia, Sickle Cell
  • Antisickling Agents
  • Humans
  • Hydroxyurea*
  • Pain
  • Patient Reported Outcome Measures*

Substances

  • Antisickling Agents
  • Hydroxyurea